QUENTIN-FROIGNANT, Charlotte; TOLLEFSON, Ann E; CLINE-SMITH, Anna; KAPPLER-GRATIAS, Sandrine; LANDREIN, Nicolas; ROY, Vincent; AGROFOGLIO, Luigi A; TOTH, Karoly; WODRICH, Harald; GALLARDO, Franck

doi:10.1021/acsinfecdis.5c00170

Metadatos

Mostrar el registro completo del ítem

Licencia de uso del documento

QUENTIN-FROIGNANT, Charlotte

TOLLEFSON, Ann E

CLINE-SMITH, Anna

Idioma

Article de revue

Este ítem está publicado en

ACS Infectious Diseases. 2025-05-19

Resumen en inglés

Adenoviruses are responsible for a range of pathologies, including respiratory infections in children. Although most adenovirus infections are self-resolving, they can cause serious illness, particularly in immunocompromised individuals. There is currently no approved treatment for adenovirus infections. Here, we report on the antiviral activity of LAVR-289, a broad-spectrum acyclonucleoside phosphonate exhibiting potent efficacy against several adenovirus serotypes, comparable to that of brincidofovir. LAVR-289 specifically inhibits viral replication, blocking the formation of viral replication centers and preventing late protein expression without affecting viral entry or delivery of viral genomes to the nucleus. , using immunocompromised Syrian hamsters infected with HAdV-C6, oral administration of LAVR-289 resulted in 100% animal survival. These results suggest that LAVR-289 holds promise as a potential therapy for adenovirus infections paving the way for a future treatment of immunocompromised patients.< Leer menos

Palabras clave en inglés

Acyclic nucleoside phosphonate prodrug; Adenovirus infection; Antiviral; LAVR-289; in vivo

Metadatos

Compartir este ítem

Licencia de uso del documento

LAVR-289, an Orally Bioavailable Inhibitor of Adenovirus Replication In Vitro and In Vivo

Idioma

Este ítem está publicado en

Resumen en inglés

Palabras clave en inglés

URI

DOI

Centros de investigación